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Objectives: The aim of this study was to evaluate the inﬂuence of a dietary strategy for weight loss
(the RESMENA [reduction of metabolic syndrome in Navarra, Spain] diet) on the expression of
inﬂammation-related microRNAS (miRNAs) and genes in white blood cells (WBC) from individuals
with metabolic syndrome (MetS).
Methods: The clinical, anthropometric, and biochemical characteristics of 40 individuals with MetS
(20 men and 20 women; age: 48.84  10.02 y; body mass index: 35.41  4.42 kg/m2) were
evaluated before and after an 8-wk hypocaloric diet based on the Mediterranean dietary pattern.
Nutrient intake was assessed with a food frequency questionnaire and 48-h weighed food records.
Total RNA was isolated from WBC and the expression of some inﬂammation-related miRNAs and
mRNAs (IL-6, TNF-a, ICAM-1, IL-18, SERPINE1, VCAM-1, GAPDH) was assessed by quantitative poly-
merase chain reaction.
Results: The RESMENA nutritional intervention improved most anthropometric and biochemical
features. The expression of miR-155-3p was decreased in WBC, whereas Let-7b was strongly
upregulated as a consequence of the dietary treatment. However, they were not correlated with
the expression of the proinﬂammatory genes in the same cells. The changes in the expression of
let-7b, miR-125b, miR-130a, miR-132-3p, and miR-422b were signiﬁcantly associated with changes
in diet quality when assessed by the Healthy Eating Index. Moreover, low consumption of lipids
and saturated fat (g/d) were associated with higher expression of let-7b after the nutritional
intervention.
Conclusions: The Mediterranean-based nutritional intervention was able to induce changes in the
expression of let-7b and miR-155-3p in WBC from patients with MetS after 8 wk. Moreover, the
quality of the diet has an important effect on the miRNAs expression changes. These results should
be highlighted because these miRNAs have been associated with inﬂammatory gene regulation and
important human diseases.
 2016 Elsevier Inc. All rights reserved.tion and analysis, decision
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Metabolic syndrome (MetS) is a complex disorder deﬁned by
a cluster of interconnected cardiometabolic alterations,
including hypertension, insulin resistance, dyslipidemia, and
abdominal obesity [1]. Individuals exhibiting combinations of
these metabolic disturbances have a substantial synergistic car-
diovascular risk greater than the sum associated with each ab-
normality [2]. Furthermore, the pathologic enlargement of the
adipose tissue in obesity leads to an elevated production of
proinﬂammatory mediators [3]. These altered signals mediate
multiple processes, which predispose to diabetes mellitus, he-
patic steatosis, atherosclerosis, plaque rupture, and athero-
thrombosis [1]. However, to date, the available information is
controversial and does not necessarily imply a causal role neither
putatively involve epigenetic mechanisms.
Data obtained from functional genomic methodologies indi-
cate that several hundred genes participate in the inﬂammatory
response and that their coordinated expression is tightly
controlled [4]. Hence, microRNAs (miRNAs) are small noncoding
RNAs that have the ability to control multiple genes, establishing
an orchestrated network governing remote processes through
intertwined pathways [5]. Several studies have highlighted the
signiﬁcance of miRNAs in maintaining metabolic homeostasis,
and the regulation of these miRNAs could serve as a potential
therapeutic target for metabolic disorders [6]. For example, the
inﬂammatory toll-like receptor/nuclear factor-kB–related miR-
181a is downregulated in monocytes of obese patients, which
is associated with a higher number of MetS components and
with coronary artery disease [7]. In this sense, miRNA expression
contributes to regulate body weight, sometimes in relation to
inﬂammation regulation [8]. Thus, some of these transcripts
could be used as prognostic biomarkers of response to hypo-
caloric diets.
The aim of this study was to evaluate the effect of a weight
loss strategy based on the Mediterranean dietary pattern (the
RESMENA [reduction of metabolic syndrome in Navarra, Spain]
diet) on anthropometric measurements, biochemical markers,
and the expression of some selected inﬂammation-related genes
andmiRNAs inwhite blood cells (WBC) of individuals with MetS.
We hypothesized that a hypocaloric pattern, as well as the
improvement of the overall diet quality components designed to
reduce MetS features, could have a positive effect on the
expression of genes and miRNAs related to the inﬂammatory
state. We sought to further explore the possible epigenetic un-
derlying mechanisms and the putative interactions with the diet.Methods
Study population
Forty white individuals (20 men and 20 women) with a body mass index
(BMI) of 35.41  4.42 kg/m2, aged 48  10 y, and diagnosed with MetS according
to the International Diabetes Federation cutoffs [9] were enrolled in this study.
The inclusion and exclusion criteria have been previously reported [10], but it
should be pointed out that individuals with presence of psychiatric disturbances,
eating disorders, chronic diseases related to the metabolism of nutrients, major
body weight changes in the previous 3 mo, and difﬁculties in changing food
habits were excluded. Volunteers were recruited through local newspaper ad-
vertisements and the database of Department of Nutrition, Food Science and
Physiology, Center for Nutrition Research, University of Navarra, Pamplona,
Spain. Calculations were based on ﬁndings of previous studies [10,11]. The study
protocol was performed in accordance with the ethical guidelines of the Decla-
ration of Helsinki, and was approved by the Research Ethics Committee of the
University of Navarra (ref. 065/2009). All individuals provided written informed
consent also approved by the same research ethics committee.Study protocol
The research is based on a subsample of the RESMENA-S study [10], a
controlled intervention study that aimed to reduce MetS features based on en-
ergy restriction over 6 mo [10,11] and with components of the Mediterranean
diet to speciﬁcally combat MetS features. The complete project is registered at
www.clinicaltrials.gov (NCT01087086) and can be accessed elsewhere [10]. The
diet of the RESMENA study prescribed an energy restriction of 30% applied to the
total energy requirements of each patient. Resting metabolic rate was calculated
using the Harris–Benedict equation, in which the Wilkens-adjusted weight was
applied [12]. The physical activity factor was considered to calculate the total
energy requirements according to the Food and Nutrition Board, National
Research Council: Recommended Dietary Allowances [13]. Fasting blood sam-
ples, habitual dietary intake, and body composition were measured at baseline
and at the end point of the 8-wk intervention period following standardized
protocols, as published elsewhere [10,12].
Diet and dietary assessments
Participants were provided a 7-dmenu plan as previously described [14]. The
plan was composed of seven meals per day, including breakfast, lunch, dinner,
two snacks in the morning, and two more snacks in the afternoon. Some char-
acteristics of the RESMENA diet were a moderately high protein intake
(24.6%  2.8%), higher daily average intake (seven meals daily), and increased
total antioxidant capacity (TAC) than the usual recommendations. Moreover, the
dietary advice included a cholesterol content <300 mg and focused on low
glycemic index and glycemic load (GL) carbohydrate meals [10,12].
Dietary intake was assessed with a semiquantitative 136-item food fre-
quency questionnaire previously validated in Spain for energy and nutrient
intake [14]. A 48-h weighed food record was required at the beginning and at the
end of the study. Diet composition was analyzed using the DIAL software (Alce
Ingenieria, Madrid, Spain). The amount of eicosapentaenoic fatty acid and do-
cosahexaenoic fatty acid was obtained through the DIAL software to estimateu-3
fatty acid intake. The Healthy Eating Index (HEI) was calculated using the DIAL
software as described elsewhere [15]. The program gives different values be-
tween 0 and 100 considering the servings per day of cereals, vegetables, fruits,
dairy products, and meat. Also, this score takes into account the percentage of
energy provided by total and saturated fats, the amount of cholesterol and so-
dium daily, and the variety of the diet. The ﬁnal value was classiﬁed into ﬁve
categories: >80 points indicates “excellent diet”; 71 to 80 points, a “very good
diet”; 61 to 70 points, a “good diet”; 51 to 60, an “acceptable diet”; and 0 to 50
points, an “inadequate diet.” Dietary TAC was calculated using a list that takes
into account raw or cooked food preparations. The dial software provides a list of
the total antioxidant content (mmol/100 g) of >3100 foods, beverages, spices,
herbs, and supplements used worldwide. The TAC value corresponding to the
different scheduled/ingested servings per day was calculated [16]. Finally, GL was
obtained from the updated international database published online by the Hu-
man Nutrition Unit, School of Molecular Biosciences, University of Sydney [17].
Anthropometric, clinical, and biochemical assessments
Anthropometric measurements (body weight, height, waist and hip cir-
cumferences) were carried out with the individuals in their underwear using
validated processes [10]. Body fat was measured by dual energy x-ray absorpti-
ometry (Lunar iDXA, software version 6.0, Madison, WI, USA) as described
elsewhere [10]. Blood pressure was recorded with a standard mercury sphyg-
momanometer (Minimus II, Riester, Junginger, Germany). Measurements were
taken three times after a 5-min resting period, following World Health Organi-
zation criteria [18].
Venous blood samples were drawn by venipuncture after a 12-h overnight
fast. The ethylenediamine tetraacetic acid plasma and serum samples and WBCs
were separated from whole blood by centrifugation at 3500 g at 5C for 15 min
(Model 5804 R, Eppendorf, Germany) and were frozen immediately at 80C
until assay (WBC in buffy coat). Glucose, total cholesterol (TC), high-density li-
poprotein cholesterol, triacylglycerols, and acid uric serum concentrations were
measured in an autoanalyzer Pentra C-200 (HORIBA ABX, Madrid, Spain) with
speciﬁc kits. Insulin concentrations were determined by an enzyme-linked
immunosorbent assay (ELISA) kit (Mercodia, Uppsala, Sweden) in a Triturus
autoanalyzer (Grifols SA, Barcelona, Spain). Insulin resistance was estimated by
the homeostasis model assessment (HOMA) index {HOMA-IR ¼ [glucose (mmol/
L)  insulin (mU/mL)]/22.5} [19]. Low-density lipoprotein cholesterol (LDL-C)
levels were calculated with the Friedewald formula: LDL-C ¼ TChigh-density
lipoprotein cholesterolvery-low-density lipoprotein [20]. Plasma malondial-
dehyde (MDA) was calorimetrically determined with a commercial kit (BIO-
XYTECH LPO-586, Oxis Research, Portland, OR, USA). Plasma-oxidized LDL-C
levels were measured using a capture-ELISA kit from Mercodia (Uppsala, Swe-
den). Plasma concentrations of plasminogen activator inhibitor (PAI)-1 (Bio-
Vendor, Germany), interleukin (IL)-6 (R&D Systems, Minneapolis, MN), tumor
Table 2
Anthropometric, biochemical, and dietary characteristics of the participants at
baseline and after 8 wk on the RESMENA Diet
Variables Baseline 8 wk P value*
Mean  SD Mean  SD
Anthropometric measurements (N ¼ 40)
Body weight (kg) 99.7  16.5 92.6  15.8 <0.01
BMI (kg/m2) 35.4  4.4 32.8  4.2 <0.01
Waist circumference (cm) 110.9  12.1 103.2  10.1 <0.01
Waist/hip ratio 0.96  0.10 0.92  0.09 <0.01
DXA total fat mass (%) 42.6  6.0 40.1  6.6 <0.01
DXA gynoid fat mass (kg) 7.96  1.74 7.33  1.66 <0.01
DXA android fat mass (kg) 3.93  0.94 3.72  0.87 0.02
DXA truncal fat mass (kg) 26.73  5.18 25.92  5.03 <0.01
Blood pressure (N ¼ 40)
SBP (mm Hg) 147.39  20.87 134.10  16.07 <0.01
DBP (mm Hg) 84.43  9.01 76.69  9.07 <0.01
Biochemical parameters (N ¼ 40)
Total cholesterol (mg/dL) 219  45 202  45 <0.01
HDL-C (mg/dL) 43  10 41  9 0.06
LDL-C (mg/dL) 137  39 131  39 0.29
Ox-LDL (U/L) 44.3  18.5 40.2  13.9 0.11
TG (mg/dL) 196  124 150  100 <0.01
Glucose (mg/dL) 124  38 109  25 <0.01
Insulin (mU/mL) 14.18  8.12 8.95  5.97 <0.01
HOMA index 4.46  3.01 2.49  1.82 <0.01
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(Demeditec, Germany) were measured using ELISA kits and an automated
analyzer system (Triturus, Grifols, Barcelona, Spain). In our laboratory, the inter-
and intra-assay variability were <10% for all analytical determinations.
RNA extraction, miRNA, and mRNA quantitative PCR
At baseline and at the end of the study, total RNA was extracted from WBC
using Trizol reagent according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA, USA). The concentration and purity of RNAwere determined at 260/
280 nm using a NanoDrop spectrophotometer (Thermo Fisher Scientiﬁc, Wil-
mington, DE, USA).
For the miRNA analysis, 20 ng of total RNAwas reverse-transcribed using the
TaqMan MicroRNA Reverse Transcription kit (Life Technologies, Foster City, CA,
USA) according to the manufacturer’s protocol and the miRNA-speciﬁc reverse-
transcription primers provided with the TaqMan MicroRNA Assay (Life Tech-
nologies), as shown in Table 1. The miRNA-speciﬁc cDNA was ampliﬁed in
triplicate with the TaqMan Universal polymerase chain reaction (PCR) master
mix and the respective speciﬁc probe provided in the TaqMan MicroRNA Assay
(Life Technologies).
To perform the mRNAs analyses, 2 mg of total RNA was reverse-transcribed
using the high-capacity complementary DNA (cDNA) reverse transcription (RT)
kit (Life Technologies) according to the manufacturer’s protocol. cDNA was
ampliﬁed in triplicate with the TaqMan Universal PCR master mix and the
respective speciﬁc probe provided in the TaqMan Gene Expression Assays (Life
Technologies; Table 1). The analyzed miRNAs and genes were selected on the
basis of previous studies strongly supporting their possible involvement in in-
ﬂammatory pathways related to MetS features.
miRNA and mRNA levels were normalized to the endogenous controls,
RNU48 and GAPDH (glycerol-3-phosphate dehydrogenase), respectively. The
DDCT method was used for quantiﬁcation and the fold changes are reported as
2DDCT [21]. All quantitative real-time RT-PCR measurements were performed
using a 7900 HT Fast Real-Time PCR system (Life Technologies).
Statistical analyses
A group size of 40 was estimated to be necessary to obtain a signiﬁcant
(P< 0.05) difference in the reduction of waist circumference of 4.3  6.8 cmwith
a power of 80% [10]. Only those individuals who completed the study were
analyzed. The results are expressed as mean  SD. Normality distributions of the
measured variables were determined according to the Shapiro–Wilk test. Dif-
ferences between the beginning and the end of the intervention period were
analyzed by a paired t test. Spearman correlation and linear regression analyses
were applied to assess the potential relationships and associations among diet,
biochemical, and anthropometrical components with miRNA and mRNA varia-
tion. Analyses were carried out using SPSS 15.1 software for Windows (SPSS Inc,
Chicago, IL, USA). P < 0.05 was considered statistically signiﬁcant.Table 1
References of the speciﬁc PCR primers/probes used for the measurement of the
miRNAs and mRNAs
miRNAs TaqMan MicroRNA Assay reference
Let-7b 002619
miR-125b 000449
miR-130a 000454
miR-132-3p 000457
miR-146a 000468
miR-155-3p 002287
miR-223-5p 002098
miR-422b 001314
miR-4772- p 464414
RUN18 001006
Genes (mRNAs) TaqMan assay reference
IL-6 Hs00985639_m1
TNF-a Hs01113624_g1
ICAM-1 Hs00164932_m1
IL-18 Hs01038788_m1
SERPINE1 Hs01126606_m1
VCAM-1 Hs01003372_m1
GAPDH Hs02758991_g1
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ICAM, intercellular adhe-
sion molecule; IL, interleukin; miR, microRNA; PCR, polymerase chain reaction;
SERPINE, serine protease inhibitor, member E; TNF, tumor necrosis factor; VCAM,
vascular cell adhesion moleculeResults
All clinical, laboratory, and dietary characteristics of study
participants at the beginning and at the end of the dietary
intervention are shown in Table 2. After 8 wk, the RESMENA diet
improved most anthropometric and biochemical markers
included in this study (Table 2). Therewas a signiﬁcant reduction
of all variables related to body weight, such as BMI, waist
circumference, and fat mass (P < 0.05). There was also a signif-
icant reduction of TC, triacylglycerols, glucose, and insulin levels
and, consequently, of the HOMA index (P < 0.05). Moreover, the
circulating levels of MDA and PAI-1 were lower when compared
with the levels at baseline (P < 0.05).Uric acid (mg/dL) 5.82  1.38 5.94  1.06 0.49
Inﬂammatory markers (N ¼ 40)
MDA (mM) 0.84  0.36 0.74  0.28 <0.01
CRP (mg/L) 3.30  3.45 3.53  5.75 0.71
IL-6 (pg/mL) 2.63  1.73 2.76  1.58 0.53
PAI-1 (pg/mL) 157  127 144  152 <0.01
TNF-a (pg/mL) 0.69  0.50 0.88  0.94 0.99
Dietary characteristics (n ¼ 35)
Energy intake (kcal/d) 2255  287 1353  559 <0.01
Meal frequency (meals/d) 5.35  1.30 6.47  1.08 <0.01
Proteins (% TCV/d) 17.1  2.8 24.5  2.8 <0.01
Lipids (% TCV/d) 44.4  6.0 37.8  7.0 <0.01
CHO (% TCV/d) 37.9  5.9 37.4  6.4 0.64
Fiber (g/d) 18.3  10.2 20.2  8.5 0.07
GI (U/d) 663  217 332  124 <0.01
GL (U/d) 112  44 53  26 <0.01
Saturated fatty acids (g/d) 34.3  13.2 16.1  5.7 <0.01
u-3 fatty acids (g/d) 0.33  0.16 0.34  0.04 0.06
TAC (mmol/d) 8.32  4.74 13.89  5.21 <0.01
Healthy Eating Index (U) 55.9  11.8 71.4  10.2 <0.01
BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure;
DXA, dual-energy x-ray absorptiometry; GL, glycemic load; HDL-C, high-density
lipoprotein cholesterol; HOMA, homeostasis model assessment; GI, glycemic
index; LDL-C, low-density lipoprotein cholesterol; MDA: malondialdehyde; ox-
LDL, oxidized low-density lipoprotein cholesterol; RESMENA, reduction of
metabolic syndrome in Navarra, Spain; SBP, systolic blood pressure; TG, tricyl-
glycerols; TCV, total caloric value
Bolded P values indicate statistically signiﬁcant (less than 0.05).
* P value: comparison by paired samples statistics from baseline (Student’s t
test).
Table 4
Spearman correlations between the relative expression of Let-7b and other
miRNAs* analyzed at baseline and after 8 wk on the RESMENA diet
Let-7b
(N ¼ 40)*
Baseline 8 wk
Correlation
coefﬁcient
P value Correlation
coefﬁcient
P value
miR-125b 0.290 0.09 0.360 0.02y
miR-130a 0.702 <0.01y 0.636 <0.01y
miR-132-3p 0.002 0.99 0.025 0.88
miR-146a 0.049 0.77 0.425 <0.01y
miR-155-3p –0.435 0.03y –0.159 0.41
miR-223-5p 0.605 <0.01y 0.674 <0.01y
miR-422b 0.441 <0.01y 0.404 <0.01y
miR-4772-3p 0.380 0.02y 0.632 <0.01y
PCR, polymerase chain reaction; RESMENA, reduction of metabolic syndrome in
Navarra, Spain
Bolded P values indicate statistically signiﬁcant (less than 0.05).
* miRNAs were measured by quantitative real-time PCR and normalized by
RNU48.
y P < 0.05.
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accordance with the recommendations provided by the
RESMENA diet. There was a lower intake of energy, lipids, and
saturated fattyacids (P<0.05). On theotherhand,meal frequency
(meals/day), protein intake, and TAC of the diet were higher
(P < 0.05) at the end of the nutritional intervention (Table 2).
These changes subsequently improved (P < 0.05) the HEI.
The analysis of the expression of proinﬂammatory genes in
WBC showed no relevant changes (P > 0.05) as a result of the 8-
wk nutritional intervention (Table 3). However, the expression of
miR-155-3p decreased (P ¼ 0.007), whereas let-7b was strongly
upregulated (P ¼ 0.002) as a consequence of the dietary inter-
vention (Table 3). However, they were not correlated with the
expression of the proinﬂammatory genes analyzed. Interestingly,
the expression of let-7bwas highly correlated (P< 0.05) with the
other miRNAs analyzed, both at baseline (miR-130a, miR-132-3p,
miR-146a, miR-155-3p, miR-223-5p, miR-422b, and miR-4772-
3p) or after the RESMENA diet (miR-125b, miR-130a, miR-146a,
miR-223-5p, miR-422b, and miR-4772-3p; Table 4).
The changes (8 wk versus baseline) in the miRNA expression
levels were statistically associated with the changes in the diet
quality, when assessed by the HEI. The improvement of HEI
positively correlated with the changes in the expression of some
miRNAs (Table 5) such as let-7b (r2¼ 0.478; P¼ 0.008), miR-125b
(r2 ¼ 0.359; P ¼ 0.047), miR-130a (r2 ¼ 0.546; P ¼ 0.001), miR-
132-3p (r2 ¼ 0.551; P ¼ 0.001), and miR-422b (r2 ¼ 0.374;
P ¼ 0.042). Some of these signiﬁcant correlations were found
even after adjustment for energy restriction, sex, and age: let-7b
(b¼ 0.425; P¼ 0.035), miR-130a (b¼ 0.469; P¼ 0.009), andmiR-
132-3p (b¼ 0.543; P¼ 0.003; Table 6). Furthermore, themiR-155
expression was associated with changes in the HEI and weight
loss in a regression model adjusted for sex and age (b ¼ 0.577;
P ¼ 0.014 and b ¼ 0.740; P ¼ 0.003, respectively; Table 6).Table 3
Relative expression (fold change) of somemiRNAs and genes (mRNAs) at baseline
and after 8 wk on the RESMENA diet
Relative expression Baseline 8-wk P value*
(N ¼ 40) Mean  SD Mean  SD
miRNAsy
Let-7b 1.04  0.63 1.51  0.90 <0.01z
miR-125b 1.22  0.84 1.33  0.72 0.70
miR-130a 1.29  0.75 1.52  0.86 0.76
miR-132-3p 0.54  0.48 0.51  0.25 0.20
miR-146a 0.57  0.23 0.58  0.25 0.83
miR-155-3p 0.89  0.49 0.59  0.27 <0.01z
miR-223-5p 0.82  0.50 0.89  0.47 0.26
miR-422b 0.70  0.43 0.74  0.36 0.13
miR-4772-3p 2.60  0.59 2.78  0.27 0.56
mRNAy
IL-6 0.62  0.47 1.05  0.86 0.20
TNF-a 1.01  0.86 1.53  1.25 0.08
ICAM-1 2.21  1.79 1.92  1.64 0.66
IL-18 2.30  2.16 1.54  1.32 0.21
SERPINE1 5.59  4.15 4.74  2.96 0.91
VCAM-1 5.21  4.62 3.02  2.32 0.30
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IL, interleukin; TNF, tumor
necrosis factor; ICAM, intercellular adhesion molecule; PCR, polymerase chain
reaction; RESMENA, reduction of metabolic syndrome in Navarra, Spain; SER-
PINE, serine protease inhibitor, member E; VCAM, vascular cell adhesion mole-
cule
Bolded P values indicate statistically signiﬁcant (less than 0.05).
* P value: comparison by paired samples after log transformation (Student’s t
test).
y miRNA and mRNA expression were measured by quantitative real-time PCR
and normalized by RNU48 and GAPDH, respectively.
z Different from baseline.Individually analyzing the components of HEI, it was evident
that intakes of lipids and saturated fatty acids (g/d) were nega-
tively associated with the expression of let-7b (r2 ¼ 0.443;
P ¼ 0.014 and r2 ¼ 0.432; P ¼ 0.017, respectively; Fig. 1), sug-
gesting that the improvement in HEI, in part as consequence of
the low consumption of lipids and saturated fat intake (g/d),
could be implicated in the increased expression of let-7 b in
WBC.
Discussion
In the present study, the effects of a novel dietary strategy on
the expression levels of miRNAs and genes related to the in-
ﬂammatory process in WBC were reported. To our knowledge,
this is a pioneer study in patients with MetS evaluating the ef-
fects of an energy-restricted intervention based on Mediterra-
nean diet principles, including a modiﬁed macronutrient
distribution and increased meal frequency, as well as theTable 5
Spearman correlations between changes in the healthy eating index and changes
in the relative expression of the miRNAs and genes analyzed*
D healthy eating Index (n ¼ 35) Correlation coefﬁcient P value
D Let-7b 0.478 <0.01y
D miR-125b 0.359 0.04y
D miR-130a 0.546 <0.01y
D miR-132-3p 0.551 <0.01y
D miR-146a 0.026 0.88
D miR-155- p 0.414 0.12
D miR-223-5p 0.023 0.90
D miR-422b 0.374 0.04y
D miR-4772-3p –0.238 0.20
D IL-6 –0.258 0.16
D TNF-a –0.059 0.75
D ICAM-1 0.058 0.74
D IL-18 0.153 0.41
D SERPINE1 0.020 0.91
D VCAM-1 –0.049 0.81
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ICAM, intercellular adhe-
sion molecule; IL, interleukin; PCR, polymerase chain reaction; SERPINE, serine
protease inhibitor member; TNF, tumor necrosis factor; VCAM, vascular cell
adhesion molecule
Bolded P values indicate statistically signiﬁcant (less than 0.05).
* Changes (8 wk vs baseline) in miRNA and gene expression weremeasured by
quantitative real-time PCR and normalized by RNU48 and GAPDH, respectively.
y P < 0.05.
Table 6
Regression coefﬁcients between changes in the healthy eating index and changes
in the relative expression of some miRNAs analyzed (N ¼ 35)*
Linear regression models ANOVA test b-coefﬁcient P value
D miR-130a
D HEI 0.024y 0.469 0.009y
Energy restriction 0.039 0.858
Age –0.028 0.866
Sex 0.337 0.053
D miR-132-3p
D HEI 0.025y 0.543 0.003y
Energy restriction 0.234 0.170
Age –0.038 0.817
Sex 0.133 0.432
D Let-7b
D HEI 0.025y 0.410 0.024y
Energy restriction –0.191 0.276
D miR-155
D HEI 0.007y 0.577 0.014y
Weight loss 0.740 0.003y
Age –0.313 0.094
Sex –0.020 0.922
ANOVA, analysis of variance; HEI, Healthy Eating Index; PCR, polymerase chain
reaction
Bolded P values indicate statistically signiﬁcant (less than 0.05).
* Changes (8 wk vs baseline) in miRNA expression were measured by quan-
titative real-time PCR and normalized by RNU48.
y P < 0.05.
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fatty acids, and controlling glycemic index and GL, dietary TAC,
and HEI score.
Metabolic diseases are characterized by the failure of regu-
latory genes or enzymes to effectively orchestrate speciﬁc
pathways involved in the control of many biological processes
[2]. In addition to the classical regulators of metabolic homeo-
stasis, recent discoveries have evidenced the putative remark-
able role of miRNAs in the post-transcriptional regulation of a
number of genes, and their involvement in many pathologic
states, such as the MetS features [22]. However, results from
human studies are still unclear and more research is needed to
ﬁnd links between miRNAs and the pathways involved.
The main results of the current study were the expression
changes of miRNA-155 and let-7b, especially the latter. Let-7
family was, after lin-4, the second miRNAs found and has nine
members, namely, let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-
7g, let-7i, and miR-98. All members are believed to exert similar
functions because they share a common seed region (nucleotides
2–8), which mediates miRNA interaction with target mRNAs
[23]. Previous studies have identiﬁed let-7 as a tumor suppressor,
which is downregulated or even lost in many human cancers
[24], regulating multiple cellular processes including cell divi-
sion and DNA repair pathways. More recently, the role of let-7 in
the physiopathology of some diseases has received signiﬁcant
attention. Furthermore, aberrant let-7 expression has been
associated with a variety of human diseases including cardio-
vascular events, liver ﬁbrosis, and lung disorders. Moreover, it
has been demonstrated that let-7b regulates both atherogenic
and adipogenic phenomena. Biostatistical tests and network
analyses suggest that let-7b could act as a global synergistic key
mediator controlling hundreds of protein-coding genes [25].
Interestingly, let-7b expression had a high correlation with all of
the miRNAs analyzed at baseline or at the end of the period
studied. A recent work suggested that let-7b could be a strong
candidate as a master regulator of products on coding and non-
coding genes related with ovarian carcinoma [25]. Otherpublications have provided new insights into the protective
properties of let-7b in preventing the endothelial dysfunction
associated with cardiovascular disease [26]. Circulating let-7b
levels were lower in patients with acute myocardial infarction
than in healthy adults [27]. Additionally, overexpression of let-7b
promoted nitric oxide production [26], which is considered a key
factor in vascular protective actions including vasodilatation.
Although this study did not imply a direct action, we found that
blood pressure was lower at the end of the dietary intervention
period.
Global knockdown of the let-7 family with an antimiR was
sufﬁcient to prevent and treat impaired glucose tolerance inmice
with diet-induced obesity, at least in part by improving insulin
sensitivity in liver and muscle [23]. In the same study, antimiR
treatment of mice on a high-fat diet also resulted in increased
lean and muscle mass, but not increased fat mass, and prevented
ectopic fat deposition in the liver. These ﬁndings demonstrate
that let-7 regulates multiple aspects of glucose metabolism and
suggests antimiR-induced let-7 knockdown as a potential treat-
ment for type 2 diabetes.
In this trial, the expression of miR-155was lower at the end of
the nutritional intervention and was associated with the quality
of the diet and with the weight loss by regression analysis. These
results suggest that miR-155 could be a prognostic marker of
obesity, as advanced by previous studies. In this context, some
authors have shown that the expression of miR-155 was higher
in diet-induced obese rats than in control animals [28]. In the
same study, a 30% calorie restriction led to signiﬁcant reduction
in the expression of miR-155. Recent ﬁndings identiﬁed miR-155
as a central apigenin-regulated miRNA in inﬂammation and
provided evidence of the underlying mechanism by which api-
genin and diets rich in apigenin, a ﬂavonoid abundant in parsley
and celery, contribute to restore homeostasis [29]. Additionally,
quercetin decreased lipopolysaccharide (LPS)-induced expres-
sion of miR-155 inmacrophages [30], highlighting the beneﬁts of
dietary interventions as a strategy to restore proper immune
function in vivo.
Overexpression of miR-155 has been reported in lung, breast,
and colon tumors [31] and has been positively associated with
intestinal inﬂammation and ulcerative colitis [32]. Furthermore,
in vivo studies have found that transgenic mice overexpressing
miR-155 in B-cell lineage (Em-miR-155) produced more TNF-a
when challenged with LPS and were hypersensitive to LPS/D-
galactosamine–induced septic shock with respect to their
normal counterparts [33]. Interestingly, miR-155 targets the lipid
phosphatase SHIP1 [34], an important signal for macrophage
activation. The exposure of cultured macrophages to LPS leads to
upregulation of miR-155, which targets the CCAAT/enhancer
binding protein b (C/EBPb) mRNA, implicated in the regulation of
proinﬂammatory cytokines during macrophage activation and
the acute-phase response [35].
To evaluate the quality of the diet, some indices or scores have
been developed, such as the HEI, the Alternate HEI, or the Diet
Quality Index and derivatives [16]. Most of these tools take into
consideration the Mediterranean diet guidelines, widely recog-
nized as a healthy pattern [36]. They consist of a single score that
results from computing different components, such as foods,
food groups, or a combination of foods and nutrients. In this
context, the HEI score was selected because it takes into account
macro- and micronutrient intake, as well as food variety. The
improvement of HEI score due to the 8-wk RESMENA interven-
tion was related to changes in the expression of let-7b, miR-125,
miR-130, miR-132, and miR-422. Additionally, the consumption
of total and saturated fat inversely correlated with the HEI and
Fig. 1. Correlations between the changes in the Healthy Eating Index (HEI) and the relative expression of let-7b and changes in the intake of lipids and saturated fat (g/d).
Spearman correlations; *P < 0.05; Changes (8 wk vs baseline); n ¼ 39 to HEI and n ¼ 30 to let-7b relative expression analysis.
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expression of these miRNAs was more dependent on the quality
of the diet than on the weight loss achieved or the energy re-
striction. To our knowledge, this was the ﬁrst time that these
associations were described in the scientiﬁc literature. It has
been previously mentioned that the diet may inﬂuence the
expression of somemiRNAs, which has been considered useful in
the assessment of nutritional status in dietary intervention
studies. For example, miR-125b has been reported to regulate in
a negative manner the expression of the vitamin D receptor
(VDR) [37]. This functional link between VDR expression and
miR-125b might explain why VDR expression is upregulated,
whereas miR-125b is downregulated in distinct types of cancer
as the genomic locus that contains miR-125b is deleted in several
cancers [37]. On the other hand, miR-125b has been reported to
post-transcriptionally regulate vitamin D3 hydroxylase (CYP24),
an enzyme that catalyzes the inactivation of vitamin D; the low
expression of miR-125b in cancer tissues may be a possible
mechanism for explaining the high CYP24 expression in cancer
tissues [38]. The inﬂuence of nutrients on the expression of other
miRNAs is still unclear, being a new promising area of nutrige-
nomic research.In this study, MDA and PAI-1 levels decreased signiﬁcantly
after the intervention. High levels of plasmaMDA, a biomarker of
lipid peroxidation, have been associated with type 2 diabetes
[39], whereas calorie-restricted dietary strategies have been
previously associated with lower MDA levels [40]. In this sense, a
recent publication revealed that Let-7b overexpression inhibited
reactive oxygen species production [26]. In this context, it can be
hypothesized that the increased expression of let-7 at the end of
the intervention may contribute to decrease reactive oxygen
species production and lipid peroxidation.
PAI-1, encoded by the SERPINE1 gene, is the principal inhibitor
of tissue plasminogen activator and urokinase, and therefore is
an inhibitor of ﬁbrinolysis [41]. This serine protease is produced
by vascular endothelium, liver, monocytes/macrophages, plate-
lets, and adipose tissue [42]. High plasma levels of PAI-1 have
been associated with higher risk for cardiovascular diseases [43].
Furthermore, PAI-1–dependent mechanisms are also implicated
in the pathogenesis of obesity, insulin resistance, and type 2
diabetes [44]. In fact, increased PAI-1 levels can be considered a
component of MetS. Clinical studies have demonstrated a strong
correlation between PAI-1 and BMI and ﬁbrinolysis. As elevated
levels of inﬂammatory cytokines could increase PAI-1
J. L. Marques-Rocha et al. / Nutrition 32 (2016) 48–5554expression, the link between obesity and elevated PAI-1 levels
could be the low-grade inﬂammatory state [45]. Although the
RESMENA dietary strategy was successful for weight loss and the
improvement of most of the anthropometric and biochemical
parameters, including PAI-1, the circulating levels of other in-
ﬂammatory biomarkers, such as CRP, TNF-a, and IL-6, were not
reduced.
The study has some limitations. First, gene expression varies
depending on the tissue or cell type [22], and it is possible that
speciﬁc miRNAs are not widely expressed in human WBC. Sec-
ond, this study speciﬁcally aimed to evaluate the association
between the variables included and conclusions on causality
cannot be measured. Also, the number of participants in this
study is not very high, but it may be proposed that type 2 errors
were overcome because important statistical differences were
found. In the analysis of before and after responses in a single
group, confounding by measured or unmeasured factors that are
potentially time varying across the time periods compared re-
mains a critical threat. However, we used statistical methods
adjusting for measured confounding factors and quantifying the
potential effect of unmeasured factors on effect estimates.
Finally, despite limitations of structured questionnaires of this
type, the advantage of food frequency questionnaire is its feasi-
bility for establishing long-term habitual dietary intake [46].
Conclusion
The results of this study provide evidence that the quality of a
Mediterranean-based nutritional intervention was related to
changes in the expression of let-7b andmiR-155-3p inWBC from
patients with MetS after 8 wk. These results should be high-
lighted because these miRNAs have been associated with
important human diseases linked to MetS, such as cancer,
atherogenic and adipogenic processes, and other inﬂammatory
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